- Home
- HOLO vs ELEV Comparison
HOLO vs ELEV Comparison
Compare HOLO & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- ELEV
- Stock Information
- Founded
- HOLO 2018
- ELEV 2019
- Country
- HOLO China
- ELEV United States
- Employees
- HOLO N/A
- ELEV N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- HOLO Technology
- ELEV Health Care
- Exchange
- HOLO Nasdaq
- ELEV Nasdaq
- Market Cap
- HOLO 24.9M
- ELEV 22.6M
- IPO Year
- HOLO N/A
- ELEV 2021
- Fundamental
- Price
- HOLO $5.12
- ELEV $0.37
- Analyst Decision
- HOLO
- ELEV Hold
- Analyst Count
- HOLO 0
- ELEV 6
- Target Price
- HOLO N/A
- ELEV $1.77
- AVG Volume (30 Days)
- HOLO 4.7M
- ELEV 1.2M
- Earning Date
- HOLO 01-01-0001
- ELEV 08-05-2025
- Dividend Yield
- HOLO N/A
- ELEV N/A
- EPS Growth
- HOLO N/A
- ELEV N/A
- EPS
- HOLO N/A
- ELEV N/A
- Revenue
- HOLO $39,771,750.00
- ELEV N/A
- Revenue This Year
- HOLO N/A
- ELEV N/A
- Revenue Next Year
- HOLO N/A
- ELEV N/A
- P/E Ratio
- HOLO N/A
- ELEV N/A
- Revenue Growth
- HOLO 42.62
- ELEV N/A
- 52 Week Low
- HOLO $4.16
- ELEV $0.22
- 52 Week High
- HOLO $608.00
- ELEV $3.09
- Technical
- Relative Strength Index (RSI)
- HOLO 44.22
- ELEV 45.79
- Support Level
- HOLO $5.07
- ELEV $0.35
- Resistance Level
- HOLO $5.59
- ELEV $0.38
- Average True Range (ATR)
- HOLO 0.85
- ELEV 0.01
- MACD
- HOLO 0.03
- ELEV -0.00
- Stochastic Oscillator
- HOLO 4.32
- ELEV 34.34
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.